Please login to the form below

Not currently logged in
Email:
Password:

medicines

This page shows the latest medicines news and features for those working in and with pharma, biotech and healthcare.

Segmentation, evolved

Segmentation, evolved

However, what this is telling us is less about pricing and precision medicine and more about an evolutionary adaption to market conditions known as contextual segmentation. ... Sanofi has done so via contextual segmentation, then targeting a specific

Latest news

More from news
Approximately 140 fully matching, plus 1,220 partially matching documents found.

Latest Intelligence

  • The threat of antimicrobial resistance The threat of antimicrobial resistance

    This means ensuring that there are clear financial rewards available to drug developers if they succeed in bringing life-saving new AMR medicines to patients.

  • Brexit Means Brexit Brexit Means Brexit

    Maintaining membership would, she said, assure a continuation of investment in innovative medicines in the UK. ... Making sure the supply of medicines is uninterrupted is essential to ensure patients in the UK and EU can get the medicines they need from

  • The challenges of making genomics a reality for patients The challenges of making genomics a reality for patients

    It ushered in a new era of what we now call personalised medicine. ... But our approach and success also hinges on patients being able to access our medicines.

  • A new era of smart pharma A new era of smart pharma

    It also ties into patient empowerment and their ability to be part of their own digital ecosystem, thus closely monitoring adherence with the goal of improving the efficacy of medicines.

  • The Patient Safety Challenge The Patient Safety Challenge

    We interviewed those working as leaders in medicine, nursing, pharmacy and patient safety within the health service.

More from intelligence
Approximately 16 fully matching, plus 401 partially matching documents found.

Latest appointments

  • Editas Medicine names James Mullen as chairman Editas Medicine names James Mullen as chairman

    Editas Medicine names James Mullen as chairman. He has previously served as CEO of Patheon. ... Genome editing company Editas Medicine has appointed James Mullen as chairman of the board of directors.

  • Nabriva Therapeutics appoints chief medical officer Nabriva Therapeutics appoints chief medical officer

    Commenting on the appointment, Dr Colin Broom, chief executive officer of Nabriva, said: “Jennifer has broad expertise in infectious diseases and internal medicine with extensive experience in both clinical development and

  • Apitope strengthens its board with new director Apitope strengthens its board with new director

    Apitope strengthens its board with new director. Dr William Jenkins joins the board following a 30-year career in clinical medicine. ... Dr Jenkins has a wealth of pharmaceutical industry experience following a 30-year career in clinical medicine and

  • Lilly appoints Maura Dickler as VP of late phase oncology development Lilly appoints Maura Dickler as VP of late phase oncology development

    She will move to the pharmaceutical company from the prestigious Memorial Sloan Kettering Cancer Center, where she currently serves as associate member, Breast Medicine Service within its Department of Medicine. ... In addition to her role at Sloan

  • José Baselga joins BMS’ board of directors José Baselga joins BMS’ board of directors

    His close engagement with emerging science across biotech and shared focus on patients brings valuable contributions to helping us advance our strategy and pipeline of transformational medicines.”.

More from appointments
Approximately 10 fully matching, plus 328 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 11 fully matching, plus 283 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Synergy Vision

Synergy Vision believe in delivering medical communications that make a difference to healthcare professionals and patients. Our synergy of pharma...

Latest intelligence

Why heading online for scientific meetings can yield greater HCP engagement
Modern conferencing methods, with enhanced digital information transfers, offer unique opportunities for greater HCP engagement....
The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...
Meet the CEO behind ReNeuron’s cutting-edge stem cell therapies
Blue Latitude Health speaks to Olav Hellebo, CEO of ReNeuron, to find out about the biotech’s latest innovation in stem cell therapy and to learn his perspective on navigating the...

Infographics